Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Emergent BioSolutions, National Institutes of Health, U.S. Department of Health and Human Services infectious news

EBS received a three-year contract from HHS for up to $447.7 million for the company's BioThrax anthrax vaccine. The contract includes $400 million to

Read the full 244 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers